

1  
2  
3 **In-concert immune dynamics during natural influenza virus infection and recovery**  
4 **in acute hospitalized patients**  
5

6 Thi H.O. Nguyen<sup>1</sup>, Marios Koutsakos<sup>1</sup>, Carolien E. van de Sandt<sup>1,2</sup>, Jeremy Chase Crawford<sup>3</sup>,  
7 Liyen Loh<sup>1</sup>, Sneha Sant<sup>1</sup>, Ludivine Grzelak<sup>4</sup>, Emma K. Allen<sup>3</sup>, Tim Brahm<sup>3</sup>, E. Bridie  
8 Clemens<sup>1</sup>, Maria Auladell<sup>1</sup>, Luca Hensen<sup>1</sup>, Zhongfang Wang<sup>1</sup>, Simone Nüssing<sup>1</sup>, Xiaoxiao Jia<sup>1</sup>,  
9 Patrick Günther<sup>1</sup>, Adam K. Wheatley<sup>1</sup>, Stephen J. Kent<sup>1,5,6</sup>, Malet Aban<sup>7</sup>, Yi-Mo Deng<sup>7</sup>, Karen  
10 L. Laurie<sup>7</sup>, Aeron C. Hurt<sup>7</sup>, Stephanie Gras<sup>8,9</sup>, Jamie Rossjohn<sup>8-10</sup>, Jane Crowe<sup>11</sup>, Jianqing Xu<sup>12</sup>,  
11 David Jackson<sup>1</sup>, Lorena E. Brown<sup>1</sup>, Nicole La Gruta<sup>8</sup>, Weisan Chen<sup>13</sup>, Peter C. Doherty<sup>1</sup>,  
12 Stephen J. Turner<sup>14</sup>, Tom C. Kotsimbos<sup>15,16</sup>, Paul G. Thomas<sup>3</sup>, Allen C. Cheng<sup>17,18\*#</sup> and  
13 Katherine Kedzierska<sup>1\*#</sup>  
14

15 **Affiliations**

16 <sup>1</sup>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty  
17 Institute for Infection and Immunity, Parkville 3010, Victoria, Australia.

18 <sup>2</sup>Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam  
19 UMC, University of Amsterdam, 1066CX, Amsterdam, Netherlands.

20 <sup>3</sup>Department of Immunology, St Jude Children's Research Hospital, Memphis 38105,  
21 Tennessee, USA.

22 <sup>4</sup>Biology Department, École Normale Supérieure Paris-Saclay, Université Paris-Saclay Cachan  
23 94230, France.

24 <sup>5</sup>Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and  
25 Central Clinical School, Monash University, Melbourne 3004, Victoria, Australia.

26 <sup>6</sup>ARC Centre for Excellence in Convergent Bio-Nano Science and Technology, University of  
27 Melbourne, Parkville 3010, Victoria, Australia.

28 <sup>7</sup>World Health Organisation (WHO) Collaborating Centre for Reference and Research on  
29 Influenza, at The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Victoria,  
30 Australia.

31 <sup>8</sup>Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash  
32 University, Clayton 3800, Victoria, Australia.

33 <sup>9</sup>Australian Research Council Centre of Excellence for Advanced Molecular Imaging, Monash  
34 University, Clayton 3800, Victoria, Australia.

35 <sup>10</sup>Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park,  
36 Cardiff CF14 4XN, United Kingdom.

37 <sup>11</sup>Deepdene Surgery, Deepdene 3103, Victoria, Australia.

38 <sup>12</sup>Shanghai Public Health Clinical Centre and Institutes of Biomedical Sciences, Key Laboratory  
39 of Medical Molecular Virology of Ministry of Education/Health, Shanghai Medical College,  
40 Fudan University, Shanghai 201508, China.

41 <sup>13</sup>Department of Biochemistry and Genetics, La Trobe Institute of Molecular Science, La Trobe  
42 University, Bundoora 3084, Victoria, Australia.

43 <sup>14</sup>Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton  
44 3800, Victoria, Australia.

45 <sup>15</sup>Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital,  
46 Melbourne 3004, Victoria, Australia.

47 <sup>16</sup>Department of Medicine, Monash University, Central Clinical School, The Alfred Hospital  
48 Melbourne 3004, Victoria, Australia.

49 <sup>17</sup>School of Public Health and Preventive Medicine, Monash University, Melbourne 3004,  
50 Victoria, Australia.

51 <sup>18</sup>Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Melbourne 3004,  
52 Victoria, Australia.

53 KLL is currently at Seqirus, Parkville 3052, Victoria, Australia.

54 \*These authors contributed equally.

55 #Corresponding authors: [kkedz@unimelb.edu.au](mailto:kkedz@unimelb.edu.au); [allen.cheng@monash.edu](mailto:allen.cheng@monash.edu).

56 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

57 **Abstract**

58 We report in-concert dynamics of 18 key immune parameters, related to clinical, genetic and  
59 virological factors, in patients hospitalized with influenza across different severity levels.  
60 Influenza disease was associated with correlated increases in IL6/IL-8/MIP-1 $\alpha$ / $\beta$  cytokines and  
61 lower antibody responses. Robust activation of circulating T follicular helper cells (cTfhs)  
62 correlated with peak antibody-secreting cells (ASC) and influenza heamagglutinin-specific  
63 memory B-cell numbers, which phenotypically differed from vaccination-induced B-cell  
64 responses. Influenza-specific CD8<sup>+</sup>/CD4<sup>+</sup> T-cells increased early in disease and remained  
65 activated during patient recovery. Here, we describe the broadest to-date immune cellular  
66 networks underlying recovery from influenza infection, highly relevant to other infectious  
67 diseases.

68

69

70 Millions of people are hospitalized with severe influenza disease annually. In 2017, an estimated  
71 9.5 million people globally were hospitalized with influenza virus lower respiratory tract  
72 infections, for a total of 81.5 million days<sup>1</sup>. Moreover, an estimated 243,000-645,000 of seasonal  
73 influenza-associated respiratory deaths occur annually<sup>2</sup>. Although seasonal influenza virus  
74 infections can cause debilitating illness leading to hospitalization and death<sup>3</sup>, viral, host and  
75 immune factors determining the disease severity are unclear, as are the precise mechanisms of  
76 why some individuals present with a mild ‘asymptomatic’ infection, while others, including  
77 previously healthy or vaccinated individuals, succumb to severe viral pneumonia and fatal  
78 influenza disease. Increased susceptibility to influenza virus infection and exacerbation of  
79 disease severity can reflect an overactivation of the innate immune system, leading to  
80 hypercytokinemia, alveolar oedema and pulmonary complications, and/or impaired humoral and  
81 cellular immunity, delaying the recovery phase. While neutralizing antibodies can reduce  
82 disease transmission and viral load, the current vaccination regimens targeting antibody  
83 responses<sup>4</sup> are often short-lived and directed against specific influenza strains, thus not  
84 protective against unpredicted influenza viruses.

85 Based on human studies of natural and experimental influenza virus infection, it is well-  
86 established that in the absence of neutralizing antibodies, pre-existing memory CD8<sup>+</sup> T cells and  
87 CD4<sup>+</sup> T cells can reduce disease severity<sup>5-14</sup>. Published evidence also associates genetic host  
88 factors, such as specific HLA types and interferon-induced transmembrane protein 3 (IFITM3)  
89 single-nucleotide polymorphisms (SNPs) with clinically poor outcomes<sup>15-18</sup>. The IFITM3  
90 rs12252-C/C genotype along with early detection of inflammatory mediators IL-6, IL-8, IL-10  
91 and MIP-1 $\beta$  measured in the blood within 48 hours of hospital admission, were associated with  
92 fatal disease outcomes in our 2013 study of hospitalized H7N9-infected patients in China ( $n=18$   
93 patients, 12 recovered, 6 died)<sup>18</sup>. In contrast, recovery from severe H7N9 infection was  
94 associated with lower cytokine levels and prominent CD8<sup>+</sup> T cell responses<sup>18</sup>. Inflammatory  
95 serum cytokines IL-6 and IL-8 have also been linked to severe seasonal and pandemic influenza  
96 virus infections in hospitalized adult patients<sup>19</sup> and predicted hospitalization in a household  
97 cohort of naturally-infected individuals, including infants, children and adults<sup>20</sup>. In critically-ill  
98 children, higher levels of blood cytokines (IL-6, IL-8, IP-10, GM-CSF, MCP-1, and MIP-1 $\alpha$ )  
99 measured within 72 hours of ICU admission correlated with fatal influenza virus infection<sup>21</sup>.

100 There is scant data on the main drivers of severe influenza resulting in hospitalization or  
101 death<sup>22,23</sup>. Previous studies of influenza-infected patient cohorts mainly focused on a very select  
102 number of immunological parameters, with only three studies combining innate  
103 (cytokines/monocytes/NK cells) and adaptive T cell immunity<sup>12,24,25</sup>, and two other studies  
104 incorporating innate immunity, T cell immunity and antibody responses<sup>10,26</sup>. The limited number  
105 of parameters measured is often due to a difficulty in obtaining longitudinal samples from  
106 acutely-infected patients combined with the amount of biological material required per assay.  
107 Only one other study, the SHIVERS report<sup>26</sup> analysed convalescent samples 2 weeks post-  
108 enrolment (along with one acute sample) and showed prolonged immune activation of innate  
109 and adaptive cellular responses in hospitalized patients compared to non-hospitalized patients.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

110 Thus, there is a clear deficiency in our understanding of the specific interplay between genetics,  
111 innate and adaptive immune responses driving recovery from acute viral pneumonia.

112 Here, we utilized longitudinal samples obtained from patients hospitalized with acute  
113 influenza disease to elucidate how innate and adaptive immune responses work in concert to  
114 resolve influenza disease. We report, at a very high level of resolution, the overall breadth and  
115 kinetics of 18 key immune parameters: the antiviral/inflammatory cytokines and chemokines,  
116 hemagglutinin (HA)-directed antibodies, HA-probe-specific B cells, antibody-secreting cells  
117 (ASCs), circulatory CD4<sup>+</sup> T follicular helper (cTfh) cells, influenza peptide/MHC-specific CD8<sup>+</sup>  
118 and CD4<sup>+</sup> T cells, IFN- $\gamma$ -producing CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, Natural Killer (NK) cells,  
119 Mucosal-associated invariant T (MAIT) and  $\gamma\delta$  T cells, and granzymes A, B, K, M and perforin  
120 expression in CD8<sup>+</sup>, CD4<sup>+</sup>, NK and MAIT cells. This comprehensive panel of immune  
121 parameters, combined with host genetic factors and patient clinical data, enabled a detailed  
122 dissection of human factors driving susceptibility, severity and recovery in patients hospitalized  
123 with seasonal influenza viruses, highly relevant to other infectious diseases, especially newly-  
124 emerging respiratory infections.

125

126

## 127 **Results**

### 128 ***Patient DISI cohort***

129 We recruited 64 patients admitted to the Alfred Hospital (Prahran, Australia) between 2014-  
130 2017 into our “Dissection of Influenza-Specific Immunity” (DISI) cohort. The inclusion criteria  
131 for the DISI study included hospital admission of consenting adult patients with influenza-like  
132 illness (ILI). The longitudinal study involved serial blood and nasal swab samples collected  
133 from influenza-PCR-positive patients (Flu+,  $n=44$ ) within 1-2 days of hospital admission to  
134 discharge and follow-up blood samples ~30 days later, allowing analyses of the recovery phase  
135 (**Fig. 1a**). Patients who were influenza-PCR-negative (Flu-,  $n=20$ ) were included as ILI-matched  
136 controls. The DISI cohort included one patient #11 who became infected with H3N2 while in  
137 hospital with AML, and died 34 days later from febrile neutropenia. We also had one death in  
138 the control group, patient #28 who was PCR-negative at admission, but subsequently became  
139 IBV-PCR-positive while in hospital and died 61 days later in ICU. The remaining cohort was  
140 admitted to the Respiratory/General Ward with one case patient #62 requiring 1 day in ICU. 53  
141 patients presented with ILI, while 6 cases and 1 control patient presented with pneumonia  
142 (**Supplementary Tables 1 and 2**).

143 We successfully recalled 80% (35/44) of Flu+ patients at a median of 41 days after  
144 disease onset and 75% of our Flu- patients (15/20, median 39 days). Overall, Flu+ patients were  
145 predominantly (55%) infected with the H3N2 influenza A virus (IAV) subtype (**Fig. 1b** and  
146 **Supplementary Table 1**), followed by the co-circulating IAV 2009 pandemic H1N1 (pH1N1)-  
147 like strain (16%) and two co-circulating influenza B virus (IBV) strains (Phuket/3073/2013  
148 (9%) and Brisbane/60/2008 (7%)), representing the dominant strains for each year in Australia.  
149 IAV-infected patients (median 58 yrs,  $n=34$ ) were significantly older than IBV-infected (45 yrs,  
150  $n=10$ ) and Flu- patients (47 yrs,  $n=20$ ) (**Fig. 1c**). Apart from age, patient demographics in Flu+  
151 and Flu- groups were well-matched, with 86% and 70%, respectively, having one or more high-  
152 risk conditions for severe influenza disease. Both groups had a median of 4 days in hospital  
153 (**Supplementary Tables 1-2**). Time in hospital was significantly lower than that for more  
154 severely-ill H7N9 cohort<sup>18</sup> with a median 14 days for recovery ( $n=12$ ,  $p<0.0001$ ) and a median  
155 of 33 days for those who died ( $n=6$ ,  $p=0.0239$ ) (**Fig. 1d**). The lower hospital burden reflects the  
156 lower severity of seasonal influenza compared to avian A/H7N9 disease.

157

### 158 ***Risk HLA class-I and IFITM3-SNPs do not contribute to disease severity in hospital settings***

159 To determine whether the risk HLA class-I and IFITM3-SNPs genetic factors contributed to  
160 influenza disease severity in hospitalized patients, we compared HLA type and IFITM3 SNP  
161 alleles between Flu+ and Flu- patients. HLA types (**Supplementary Table 2**) were grouped  
162 according to “universal” or “risk” alleles based on studies describing HLA-A\*02:01/03:01 and  
163 HLA-B\*08:01/18:01/27:05/57:01 molecules binding universally conserved influenza peptides<sup>27</sup>,

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

164 versus HLA-A\*24:02/68:01 types positively correlating with pH1N1 mortality<sup>15</sup> and  
165 morbidity<sup>16</sup>. Given that our cohort was mainly Caucasian (82% Flu+, 95% Flu-,  
166 **Supplementary Table 1**), the frequencies of universal and risk alleles were comparable  
167 between two groups (**Fig. 1e**). Similarly, for IFITM3 SNP analyses, the non-risk rs12252-T/T  
168 homozygous allele was observed in 91% of Flu+ patients (remaining were C/T heterozygous)  
169 and 100% of Flu- patients, whereas the risk C/C homozygous allele was absent (**Fig. 1f**). The  
170 rs34481144 SNP showed a higher frequency of the A/G-heterozygous allele for both groups  
171 (41% and 50%, respectively), with equal or similar proportions of the risk A/A and non-risk  
172 G/G homozygous alleles (**Fig. 1g**). Further analyses of Flu+ patients with the risk A/A  
173 rs34481144 SNP versus Flu+ patients with A/G-heterozygous allele and non-risk G/G  
174 homozygous alleles showed no differences in disease severity in hospital settings, as measured  
175 by sequential (sepsis-related) organ failure assessment (SOFA) scores<sup>28</sup> (**Fig. 1h**).

176

### 177 *Highly correlated cytokines cluster together during influenza virus infection*

178 Hypercytokinemia of early inflammatory mediators (IL-6, IL-8, IL-10, MCP-1, MIP-1 $\alpha$  and  
179 MIP-1 $\beta$ ) have been associated with an increase in disease severity causing death in a number of  
180 hospitalized cohorts<sup>18-21</sup>. Pro-inflammatory cytokines and chemokines measured in the blood of  
181 acute representative Flu+ patients showed increased cytokine levels, particularly IL-6 and IL-8,  
182 between mild and moderate patients as defined by lower (0-1) or higher (2-6) SOFA scores,  
183 respectively, and in the more severe patient requiring ICU support (**Fig. 1i**). Heightened IL-6  
184 levels were also associated with the more severe 2013 H7N9-infected patients (**Fig. 1i**)<sup>18</sup>. After  
185 adjusting for age and the sampling time after days of disease onset, IL-6, IL-8, MIP-1 $\alpha$  and  
186 MIP-1 $\beta$  were significantly, strongly positively correlated with each other early after infection at  
187 V1 timepoint. This inter-correlated cytokine cluster was still strongly present at convalescence,  
188 with less significant correlations with other cytokines/chemokines (**Fig. 1j**). Therefore, our data  
189 support previous reports that IL-6, IL-8, MIP1 $\alpha$  and MIP-1 $\beta$  serve as biomarkers for severe  
190 influenza disease.

191

### 192 *Antibody responses increase in magnitude and breadth at convalescence*

193 The annual influenza vaccine is provided for free for high-risk groups under the National  
194 Immunisation Program. Despite the high proportion of Flu+ patients in this cohort being defined  
195 as high-risk due to pre-existing comorbidities (86%), only 48% of these patients were  
196 vaccinated against influenza prior to infection, compared to 65% of Flu- patients  
197 (**Supplementary Table 1**). There was rapid antigenic drifting of the H3N2 viruses between  
198 2014-2017, with more annual updates of the H3-HA vaccine component compared to the less  
199 variable H1-HA and B-HA components (**Supplementary Table 3**). Rapid drift of the H3N2  
200 component was evident in the viral HA-sequence analyses of nasal swabs from H3N2-infected  
201 patients with sufficient RNA. All 12 H3N2 viruses isolated from patients, including 9 who had  
202 been vaccinated, were from a different H3N2 clade when compared to the current H3N2  
203 seasonal vaccine strain (**Fig. 2a**). Conversely, fewer H1-HA and B-HA sequence variations were  
204 observed between isolates from the infected patients compared to the WHO reference strains  
205 (**Supplementary Fig. 1**). Interestingly, despite the H3N2 clade-mismatches, all H3N2-infected  
206 patients (except one A/unsubtyped patient) generated HA inhibition (HAI) antibody titres of 40  
207 and above (equivalent to  $\log_2(\text{HAI}/10) \geq 2$ ) against the H3 vaccine strain (same year as infection)  
208 at follow-up, compared to 54% at acute timepoints (**Fig. 2b**), suggesting a boost in strain-  
209 specific antibodies that may have contributed to the significant increase in vaccine-strain titres  
210 ( $p < 0.0001$ ). However, only marginal increases in antibody titres were observed in H1- and B-  
211 infected patients at follow-up (**Fig. 2b**). Geometric mean titres (GMT) were low for all three H1,  
212 H3 and B subtypes during acute infection, but their ability to mount antibody responses at  
213 follow-up was generally comparable to vaccine-induced responses in a healthy cohort but with  
214 greater GMT fold-changes (**Fig. 2c,d**). As expected, antibody titres were low and remained  
215 unchanged in the Flu- group (**Fig. 2c,d**).

216

217 Previous exposures to past influenza strains, influenced by age, can affect our immune  
responses to current influenza virus infections<sup>29</sup>. To study the breadth of antibody responses,

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

218 HAI antibody landscapes were generated against current and older influenza strains from the last  
219 century that the patients may have previously encountered (**Supplementary Table 3**). Antibody  
220 responses to past strains were minimal during acute infection (V1 and V2) (**Fig. 2e,f**). However,  
221 at follow-up, Flu+ patients induced robust antibody responses to older strains from the same  
222 subtype that they were infected with, a phenomenon known as back-boosting<sup>29</sup>, but not against  
223 the other subtypes (**Fig. 2e,f**). Therefore, compared to the Flu- and healthy cohorts, Flu+  
224 patients started with lower antibody titres at hospitalization, perhaps due to lower vaccine  
225 coverage, but were able to mount robust and broad antibody responses at convalescence.  
226

### 227 **Activation of cTfh, ASCs and influenza-specific memory B cells prior to recovery**

228 Tfh cells are essential for generating high-affinity memory B cells in germinal centers (GCs)  
229 and are located in secondary lymphoid organs<sup>30</sup>. cTfh cells share phenotypic and functional  
230 properties to GC Tfh cells, and we and others showed that inactivated influenza vaccination  
231 (IIV) induces expansion and PD-1/ICOS-activation of CD4<sup>+</sup>CXCR5<sup>+</sup>CXCR3<sup>+</sup> cTfh type-1  
232 (cTfh1) cells, which correlated with antibody and CD19<sup>+</sup>CD27<sup>hi</sup>CD38<sup>hi</sup> ASC responses<sup>4,31</sup>.

233 Here, we show for the first time that activated PD-1<sup>+</sup>ICOS<sup>+</sup> cTfh1 cells emerged within  
234 influenza-infected patients in parallel with ASC responses, both peaking between days 7-10  
235 after disease onset in both Flu+ and Flu- groups, prior to patients' recovery. cTfh1 cells peaked  
236 higher in Flu+ patients compared to Flu- groups, as shown by the separation of the 95%  
237 confidence intervals (**Fig. 3a-c, Supplementary Fig. 2a**). The number of ASCs was  
238 significantly higher (~2-8 fold) during acute infection compared to follow-up for both Flu+ and  
239 Flu- groups (**Fig. 3d**). Overall, activated cTfh1 cells were also trending higher at acute  
240 compared to follow-up (~2 fold,  $p=0.0519$ , Mann-Whitney test, **Fig. 3e**). Specifically, numbers  
241 of activated cTfh1 cells in Flu+ patients were significantly higher than the cTfh2 and cTfh17  
242 subsets, at both acute and follow-up timepoints (**Fig. 3e**). Further, cTfh1 responses strongly  
243 correlated with ASC responses during acute influenza virus infection (**Fig. 3f**), but less so for  
244 cTfh2 and cTfh17 subsets (**Supplementary Fig. 3**). Acute ASC responses also correlated with  
245 high antibody responses ( $\log_2(\text{HAI}/10) \geq 2$  or  $\text{HAI} \geq 40$ , **Fig. 3g**). However, acute cTfh responses  
246 did not significantly correlate with antibody responses, perhaps due to the low titres observed in  
247 some patients during acute infection, in contrast to a vaccination response where IIV-induced  
248 cTfh1 responses correlated with the fold-change in antibody titres (d28 over d0 baseline)<sup>4</sup>.

249 To evaluate influenza-specific memory B cell responses during natural influenza virus  
250 infection in comparison to vaccination, recombinant HA probes relevant to the 2014-2017  
251 vaccine strains were used to detect class-switched IgD<sup>-</sup> HA-specific B cells in Flu+ patients  
252 (**Fig. 3h, Supplementary Fig. 2b**). These rHA probes have been extensively validated for their  
253 specificity<sup>4,32,33</sup>. Numbers of rHA<sup>+</sup>IgD<sup>-</sup> B cells in total and per probe did not significantly  
254 change between acute and follow-up timepoints (**Fig. 3i**), and were comparable to the  
255 magnitudes observed following IIV<sup>4</sup>. Phenotype and isotype distributions of the total B cells  
256 remained stable between acute and follow-up timepoints (**Fig. 3j,k**). Specifically, rHA<sup>+</sup>IgD<sup>-</sup> B  
257 cells for H3 and B probes were more CD21<sup>lo</sup>CD27<sup>hi</sup> activated memory in proportion at the acute  
258 timepoint compared to follow-up (H3:  $p=0.0007$ , B:  $p=0.0017$ ), before becoming more  
259 CD21<sup>hi</sup>CD27<sup>hi</sup> resting memory at follow-up compared to acute timepoints (H3:  $p=0.0004$ , B:  
260  $p<0.0001$ ) (**Fig. 3j,l** top panels). Conversely, in a healthy vaccinated cohort, the resting memory  
261 phenotype was most prominent at baseline, before becoming more activated memory from days  
262 7-28 following IIV (**Fig. 3m**, top panel). The isotype distribution in Flu+ patients was enriched  
263 for IgG/IgM<sup>+</sup> cells (mostly IgA<sup>+</sup>) for H3, and IgA<sup>+</sup> cells for the B-probe at acute timepoints,  
264 before becoming largely IgG<sup>+</sup> at follow-up for each probe (**Fig. 3j,l** bottom panels). In contrast,  
265 the isotype distribution of rHA<sup>+</sup>IgD<sup>-</sup> B cells did not change in healthy donors following IIV  
266 (**Fig. 3m**, bottom panel). Thus, our analyses show striking differences after influenza virus  
267 infection compared to vaccination of recruited rHA<sup>+</sup>IgD<sup>-</sup> B cells at both phenotypic and isotype  
268 levels.

269 Although patients' HA-specific B cell responses did not positively correlate with their  
270 acute antibody responses which were generally low, there was a significant positive correlation  
271 between activated or resting memory HA-specific B cells with their acute ASC response, as well  
272 as resting memory HA-specific B cells with the acute cTfh responses (**Supplementary Fig. 4**).

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

273 Taken together, we show prominent activation of cTfh1 cells during acute influenza virus  
274 infection, at the time of the ASC and influenza-specific memory B cell responses.

275

### 276 ***Influenza-specific adaptive CD8<sup>+</sup> and CD4<sup>+</sup> T cells respond early after infection***

277 Our previous work showed that rapid recovery from severe A/H7N9 was associated with early  
278 IFN- $\gamma$ -producing CD8<sup>+</sup> T cell responses, while late recovery involved a network of humoral  
279 (Abs) and cellular (CD8<sup>+</sup>, CD4<sup>+</sup>, NK) responses<sup>12</sup>. Here, Flu+ patients' PBMCs were incubated  
280 with live seasonal H1N1, H3N2, B/YAM and B/VIC viruses to measure influenza-specific  
281 innate (NK,  $\gamma\delta$ , CD161<sup>+</sup>TRAV1-2<sup>+</sup> or MAIT cells) and adaptive (CD4<sup>+</sup> and CD8<sup>+</sup> T cells)  
282 immune responses elicited via IFN- $\gamma$  production after 18 hrs (**Fig. 4a,b, Supplementary Fig.**  
283 **5a**). Kinetics of influenza-specific IFN- $\gamma$ -producing cells across days after disease onset showed  
284 low numbers of IFN- $\gamma$ -producing populations across all cell subsets at patients' admission.  
285 These however increased over the course of infection, before stabilizing at convalescence (**Fig.**  
286 **4c**). Despite lymphopenia, a fixed number of cells were added to the assay, and therefore the  
287 ability of adaptive CD8<sup>+</sup> and CD4<sup>+</sup> T cells to generate IFN- $\gamma$ -responses, as a frequency per  
288 subset, continued to increase during acute infection until ~15 days after disease onset (**Fig. 4d**).  
289 Conversely, for innate cells, their ability to produce IFN- $\gamma$  responses did not change, further  
290 suggesting that adaptive T cells can increasingly respond to the virus during acute infection and  
291 are the main drivers of early recovery.

292

### 293 ***Cytolytic potential of MAIT, NK and CD8<sup>+</sup> T cells in Flu+ patients***

294 To assess the cytolytic potential within the Flu+ patients' cell subsets, we measured cytotoxic  
295 molecules: granzymes (A, B, K and M) and perforin (**Supplementary Fig. 6a**). Overall, MAIT  
296 cells had the highest frequency of total cytotoxic molecules expressed, followed by NK cells and  
297 CD8<sup>+</sup> T cells, with minimal production in CD4<sup>+</sup> T cells (**Fig. 4e**). However, for MAIT cells, the  
298 Flu+ patients at acute and convalescence exhibited significantly lower levels compared to  
299 healthy donors (demographics in **Supplementary Table 4**), but on the contrary for NK cells,  
300 possibly suggesting differences in degranulation kinetics. No differences were observed for  
301 CD8<sup>+</sup> and CD4<sup>+</sup> T cell subsets. Individual expression of cytolytic molecules revealed different  
302 patterns between cell subsets and cytolytic molecules (**Fig. 4f**). Patient NK cells had  
303 significantly higher levels of granzymes (A, B, M) and perforin compared to healthy donors, but  
304 significantly lower levels of granzyme K. Patient MAIT cells expressed lower levels of  
305 granzyme A compared to healthy donors, while patient MAIT and CD8<sup>+</sup> T cells had lower  
306 granzyme K and perforin expression. No significant differences were observed between acute  
307 and follow-up subsets. Furthermore, co-expression of multiple cytolytic molecules (4+) was  
308 significantly reduced in Flu+ patients, both at acute and follow-up, compared to healthy  
309 individuals across all cell subsets (NK cells: acute vs healthy  $p=0.0002$ ,  $p<0.0001$  for all  
310 comparisons) (**Fig. 4g**), most likely reflecting their degranulation activities during influenza  
311 infection.

312

### 313 ***Immune dynamics of activated memory influenza-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses***

314 To dissect epitope-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells during acute IAV infection, we performed  
315 patient-specific tetramer staining, utilizing an extensive range of peptide/MHC class-I and class-  
316 II tetramers covering the most frequent HLA alleles, with an estimated population coverage of  
317 63-100% across all ethnicities (**Fig. 5a, Supplementary Table 5**). Following tetramer-  
318 associated magnetic enrichment (TAME), robust tetramer<sup>+</sup>CD8<sup>+</sup> T cell populations were  
319 detected for all donors ( $n=19$ ) and specificities tested directly *ex vivo* (**Fig. 5b,c,**  
320 **Supplementary Fig. 6b,c**), even when using 10-20% less cell numbers generally required for  
321 successful detection of antigen-specific CD8<sup>+</sup> T cells in healthy donors<sup>34-36</sup>. In 17 patients,  
322 tetramer<sup>+</sup>CD8<sup>+</sup> T cell populations were detected at all the timepoints, while two patients had  
323 tetramer<sup>+</sup>CD8<sup>+</sup> T cells directed towards the subdominant B7-NP epitope detectable only at  
324 follow-up. For comparison, A2-M1-tetramer<sup>+</sup>CD8<sup>+</sup> T cells were also measured in Flu- patients  
325 ( $n=4/4$  detected) (**Fig. 5d**). Apart from CD8<sup>+</sup> T cells, we also identified influenza-specific CD4<sup>+</sup>  
326 T cells in 5/5 H3N2-infected patients with either HLA-DR\*01:01-, DR\*04:01- or DR\*11:01-

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

327 HA-tetramers (**Fig. 5e,f**), despite ~10-fold lower numbers of antigen-specific CD4<sup>+</sup> T cells *ex*  
328 *vivo*. DR\*15:02-HA tetramers were also tested but yielded no specific cells in 2/2 patients.

329 Overall, tetramer precursor frequencies (where 10<sup>-3</sup> denotes 1 per 1,000 cells or 1e-3),  
330 were stable across timepoints, with no significant differences observed between acute and  
331 follow-up (**Fig. 5f**). Pooled tetramer<sup>+</sup>CD8<sup>+</sup> T cell precursor frequencies in Flu+ patients  
332 (mean±SD, range: 2.62e-4±6.37e-4, 8.07e-7 to 3.56e-3) and Flu- patients (7.00e-5±8.11e-5,  
333 8.38e-6 to 2.65e-4) were significantly higher 79-fold (*p*<0.0001) and 21-fold (*p*=0.0026),  
334 respectively, than pooled tetramer<sup>+</sup>CD4<sup>+</sup> T cells (3.30e-6±3.20e-6, 6.19e-7 to 1.17e-5)  
335 (**Supplementary Fig. 6d**). Frequencies of pooled tetramer<sup>+</sup>CD8<sup>+</sup> T cells were similar between  
336 Flu+ and Flu- patients and fell within the ranges we described previously for HLA-A2<sup>+</sup> H7N9-  
337 Flu+ patients<sup>37,38</sup>.

338 Although the frequency of tetramer<sup>+</sup>CD8<sup>+</sup> T cells were similar between acute and  
339 follow-up timepoints in Flu+ patients, and Flu+ versus Flu- patients, the activation phenotypes  
340 markedly differed. Based on four activation markers expressed (CD38, HLA-DR, PD-1 and  
341 CD71), higher levels of activation were detected at the acute timepoint compared to follow-up  
342 (**Fig. 5g, Supplementary Fig. 6e**). Notably, in Flu+ patients, expression of two or more  
343 activation markers was most evident between days 6-10 of disease onset for A2-M1<sup>+</sup>CD8<sup>+</sup> T  
344 cells, which was in stark contrast to the mainly single-PD-1 expressing or non-activated  
345 phenotypes exhibited among the Flu+ follow-up samples, Flu- patients (**Fig. 5h**), and the parent  
346 CD8<sup>+</sup> T cell populations. High levels of activation at acute compared to follow-up samples were  
347 clearly observed across all tetramer<sup>+</sup>CD8<sup>+</sup> T cell specificities and, despite limited numbers, in  
348 tetramer<sup>+</sup>CD4<sup>+</sup> T cells when compared to parental CD8<sup>+</sup> and CD4<sup>+</sup> T cell populations (**Fig. 5i**,  
349 **Supplementary Fig. 7**).

350 Similarly, analysis of CD27/CD45RA/CD95 phenotypes showed significant differences  
351 in the activation of tetramer<sup>+</sup> CD8<sup>+</sup> and CD4<sup>+</sup> T cells in Flu+ patients when compared to the  
352 parental CD8<sup>+</sup> and CD4<sup>+</sup> T cell populations at acute and follow-up timepoints. In general,  
353 among Flu+ patients, tetramer<sup>+</sup>CD8<sup>+</sup> T cells consisted of central memory-like (Tcm,  
354 CD27<sup>+</sup>CD45RA<sup>-</sup>) and, to a lesser extent, effector memory-like (Tem, CD27<sup>-</sup>CD45RA<sup>+</sup>)  
355 phenotypes, while tetramer<sup>+</sup>CD4<sup>+</sup> T cells were predominantly of Tcm-like cells. (**Fig. 5j**,  
356 **Supplementary Fig. 6f**). These proportions remained stable across timepoints but were  
357 significantly enriched in Tcm compared to the overall CD4<sup>+</sup> and CD8<sup>+</sup> T cell populations,  
358 respectively.

359 Overall, we show an extensive breadth of highly activated, non-cultured, *ex vivo*  
360 influenza-specific memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells detected during acute IAV infection, which  
361 were still present in a less activated state following recovery.

362

### 363 **Immune correlates of influenza severity**

364 We also probed clinical, genetic and immune correlates of influenza severity and patients'  
365 recovery. We found no significant associations between influenza disease severity (SOFA  
366 scores 0-6, clinical presentation: ILI and/or pneumonia), clinical parameters (age, sex, influenza  
367 strain, days of disease onset, days in hospital, risk factors and vaccination status) and genetic  
368 host factors (IFITM3 rs34481144 SNP alleles). This might be as the majority of hospitalized  
369 DISI patients were already in high-risk groups based on their co-morbidities/risk factors (86%  
370 Flu+, 70% Flu-), including chronic respiratory disease (61% Flu+, 40% Flu-). Furthermore,  
371 patients infected with seasonal influenza viruses experienced less severe disease, with short  
372 hospital stays, no requirements for mechanical ventilation, and only one patient requiring ICU  
373 for one day, in contrast to the more severe avian H7N9-infected patients<sup>18</sup>.

374 To investigate any potential links between the overall breadth of immune responses in  
375 human influenza disease, including cytokines, antibodies, ASCs, activated cTfh1s, IFN-γ-  
376 producing innate (NK, γδT, MAIT cells) and adaptive (CD4<sup>+</sup> and CD8<sup>+</sup> T cells) immune cells,  
377 and key clinical/genetic parameters and SOFA scores as a measure for disease severity, we  
378 generated heat maps with all of the above mentioned parameters. Unsupervised heat maps of  
379 acute and convalescent timepoints were generated for both Flu+ (**Fig. 6a,b, Supplementary**  
380 **Fig. 8a,b**) and Flu- groups, as well as the entire cohort (**Supplementary Fig. 8c-e**). For Flu+ at

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

381 the acute timepoints, regions of relatively lower cytokine levels of IL-6, MIP-1 $\alpha$ , IL-8, MIP-1 $\beta$ ,  
382 MCP-1, were linked to higher levels of functional IFN- $\gamma$ -producing immune cells, ASCs and  
383 activated cTfh1s (**Fig. 6a**). As shown in **Fig. 1j**, these cytokines were strongly positively  
384 correlated to each other. At convalescence, lower cytokine regions were linked to higher IFN- $\gamma$ -  
385 producing immune cells, but not ASCs or activated cTfh1 cells, which peaked during acute  
386 infection (**Fig. 6b**). In both acute and convalescent phases, reciprocal regions of higher  
387 cytokines levels and lower IFN- $\gamma$ -producing immune cells (and lower ASCs and activated cTfh1  
388 cells for acute) were observed. However, these observed regions were not defined specifically  
389 by SOFA scores or other clinical/genetic parameters.

390 Based on the functional implications of IFN- $\gamma$ -producing cells detected here and our  
391 previous H7N9 study<sup>12</sup>, we analyzed specifically the numbers of IFN- $\gamma$ -producing cells across  
392 acute (V1) and convalescent timepoints (F<sub>up</sub>) as a function of patients' disease severity via  
393 binned SOFA scores due to unequal numbers of SOFA scores across the cohort, skewing  
394 towards low (0-1) SOFA scores, classifying the least severe. At the earliest acute timepoint  
395 (V1), decreases in innate IFN- $\gamma$ -producing  $\gamma\delta$ T and MAIT cells were significantly associated  
396 with more severe patients with higher SOFA scores (2-6) (**Fig. 6c**), but not for NK cells, CD4<sup>+</sup>  
397 and CD8<sup>+</sup> T cells. In contrast, at convalescence, lower adaptive IFN- $\gamma$ -producing CD4<sup>+</sup> and  
398 CD8<sup>+</sup> T cell responses were associated with higher severity (**Fig. 6c**). These results indicated  
399 that early influenza-specific NK, CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses were important in driving  
400 patients' recovery from influenza disease, and less severe patients had more robust responses at  
401 convalescence, while deficiencies in early innate  $\gamma\delta$ T and MAIT cell responses impacted disease  
402 severity.

403  
404

## 405 Discussion

406 We studied longitudinal samples obtained from patients hospitalized with influenza disease to  
407 determine how innate and adaptive immune cellular responses work together to resolve human  
408 influenza disease. Influenza susceptibility was associated with high co-morbidities, including  
409 people with chronic respiratory disease and immunosuppressed, lower antibody responses and  
410 lower rates of vaccination in our cohort. Influenza infection was associated with positively  
411 correlated clusters of IL6/IL-8/MIP-1 $\alpha$ /MIP-1 $\beta$  cytokines. Antibody responses were low at  
412 hospitalization but increased against current and older strains at convalescent phase. The  
413 kinetics of activated cTfh-type 1 cells correlated with ASCs and influenza-specific memory B-  
414 cell responses, which differed to vaccination-induced B-cell responses. While IFN- $\gamma$ -producing  
415 innate cell responses were unchanged, influenza-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses  
416 increased early from disease onset and tetramer<sup>+</sup> CD4<sup>+</sup> and CD8<sup>+</sup> T cells were highly activated.  
417 Collectively, these adaptive cellular mechanisms of cTfh cells, ASCs, influenza-specific B cells  
418 and T cells all preceded patients' recovery, similarly to that recently detailed in our COVID-19  
419 case report<sup>39</sup>.

420 Similarly broad and early immunologic analyses of matched hospitalized ILI controls  
421 and follow-up samples for both Flu+ and Flu- patients after ~30 days post-discharge have not  
422 previously been reported. Our work expands substantially on the SHIVERS study, which  
423 included follow-up sampling with blood samples collected from mild non-hospitalized and  
424 severe hospitalized influenza-infected patients at the acute phase and at 2 weeks post-enrolment  
425 during the 2013 New Zealand winter seasons (Aug-Oct)<sup>26</sup>. The SHIVERS cohort was similar to  
426 DISI, enrolling 27 hospitalized patients predominantly infected with a H3N2 virus (83%) and  
427 76% with an underlying condition. However, our study differed from the SHIVERS study by the  
428 more rapid enrollment following symptom onset (DISI: 4.5 $\pm$ 4.4 days (mean $\pm$ SD) compared to  
429 SHIVERS:10.7 $\pm$ 4.8 days) and our patients were hospitalized for longer (DISI median of 4 days  
430 (range 1-38 days) compared to SHIVERS median of 2 days (1-10 days). Rapid recruitment and  
431 longer hospitalization with serial sampling enabled the capture of integral immune response  
432 kinetics very early during the first week of infection, at a time critical for determining patient  
433 outcome.



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

434 Our cytokine analyses showed that inflammatory cytokines IL-6, IL-8, MIP-1 $\alpha$  and  
435 MIP-1 $\beta$  were strongly positively correlated with each other, after adjusting for age and the  
436 sampling days from disease onset, and supports previous studies on their collective role as  
437 biomarkers for influenza severity<sup>18-21</sup>. These cytokine correlations were still robust following  
438 recovery at the convalescent phase compared to other cytokines that were only correlated with  
439 each other during acute infection. Furthermore, lower expression of IL-6, IL-8, MIP-1 $\alpha$  and  
440 MIP-1 $\beta$  were associated with higher IFN- $\gamma$ -producing immune cells following influenza virus  
441 infection assay, as well as ASCs and activated cTfh1 cells, and vice versa.

442 For antibody responses, HAI antibody titres were lower in Flu+ patients during acute  
443 infection compared to Flu- patients and healthy controls, but increased significantly following  
444 recovery against the infected strain and previous strains from the same subtype. It is unclear  
445 whether the SHIVERS study compared antibody responses between acute versus convalescent  
446 phase within mild non-hospitalized and severe hospitalized patient groups, although they did not  
447 observe any differences when comparing antibody responses of mild versus severe groups at  
448 both acute and convalescent timepoints<sup>26</sup>. Given that we observed back-boosting of cross-  
449 reactive antibody responses post-infection at the follow-up timepoint, we postulate that having a  
450 natural influenza virus infection, compared to a vaccine-induced response, elicits more effective  
451 cross-reactive antibody responses post viral clearance warranting further investigations.  
452 Furthermore, acute GMT antibody titres were all below 40 and lower than the Flu- group  
453 suggesting that these antibody levels were not protective prior to infection. These findings  
454 provide a strong argument for influenza vaccination since the Flu+ group had lower vaccine  
455 coverage (48%) than the Flu- group (65%) and supports WHO's guideline of 40 being the 50%  
456 protective cut-off which has been controversial. Influenza vaccination is of utmost importance in  
457 this cohort given that 86% of Flu+ patients had a significant risk factor for severe influenza  
458 disease and 71% of those having a chronic respiratory disease.

459 We have recently performed a comprehensive study to measure influenza-specific B and  
460 T cell responses following seasonal IIV in healthy individuals<sup>4</sup>. Vaccine-induced antibody  
461 responses positively correlated with increases in ASCs, influenza-specific memory B cells and a  
462 subset of activated cTfh cells. Similarly, during acute influenza disease, we show prominent  
463 activation of cTfh1 cells, which correlated with ASC responses and memory influenza-specific  
464 B cells. In contrast, numbers of cTfh1 did not correlate with antibody titres at acute, follow-up  
465 or fold-change titres. Only ASC numbers positively correlated with higher acute antibody titres  
466 of 40 and above, again supporting a cut-off titre of 40 as a measure of protection. The role of  
467 cTfh cells as surrogates to germinal center Tfh cells have been described during dengue  
468 infection<sup>40</sup> and very recently by our group in a COVID-19 patient<sup>39</sup>. However, to the best of our  
469 knowledge, there have been no previous reports on human cTfh cells following natural influenza  
470 virus infection.

471 Interestingly, phenotypic analysis of the memory influenza-specific B cell response  
472 showed contrasting profiles induced by infection versus vaccination. During acute infection,  
473 influenza-specific B cells were of an activated-memory phenotype comprising IgG and IgA  
474 isotypes but were predominantly a resting-memory IgG<sup>+</sup> population at convalescence.  
475 Conversely, IIV induced an expansion of activated-memory influenza-specific B cells but there  
476 were no changes in the isotype distribution which were predominantly IgG<sup>+</sup> B cells, given that  
477 the influenza vaccine is not delivered to a mucosal site. IgA<sup>+</sup> memory B cells are able to localize  
478 in the blood and mucosal sites of inflammation such as the respiratory tract during influenza  
479 virus infection to provide a rapid immune response, while IgG<sup>+</sup> memory B cells generally  
480 circulate throughout the body<sup>45</sup>. Therefore, in accordance with our earlier antibody findings, we  
481 suggest that future B cell-based influenza vaccines promoting cross-reactive B cell responses  
482 encompassing both activated-memory IgA<sup>+</sup> and IgG<sup>+</sup> subclasses may provide further protection  
483 at the site of infection.

484 Our study utilized a whole live virus assay to measure the kinetics of influenza-specific  
485 responses in NK cells,  $\gamma\delta$  T cells and CD161<sup>+</sup>TRAV1-2<sup>+</sup> MAIT cells (innate-like), and CD8<sup>+</sup>  
486 and CD4<sup>+</sup> T cells (adaptive). We observed robust and increasing proportions of adaptive CD8<sup>+</sup>  
487 and CD4<sup>+</sup> T cell responses within the first 2 weeks of infection, despite the patients' overall

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

488 lymphopenic state, illustrating the ability of these cell types to drive patient recovery. In  
489 contrast, innate lymphocytes did not increase in their ability to respond to influenza virus  
490 infection by cytokine production, and lower IFN- $\gamma$ -producing  $\gamma\delta$  T cells and MAIT cells were  
491 significantly associated with higher disease severity based on SOFA scores at the earliest V1  
492 timepoint. Similarly, we previously showed the robustness of the adaptive CD8<sup>+</sup> and CD4<sup>+</sup> T  
493 cell immune response in driving recovery from severe H7N9 disease<sup>12</sup>. These findings have  
494 important implications for future influenza vaccines because, apart from the CD4<sup>+</sup> T cell help  
495 compartment, IIV fails to induce CD8<sup>+</sup> T cell responses nor any innate responses from NK cells,  
496  $\gamma\delta$  T cells and MAIT cells, as we previously reported<sup>4</sup>.

497 We probed influenza-specific T cells *ex vivo* using a range of peptide/MHC class I and  
498 class II tetramers covering the most frequent HLA alleles with an estimated population coverage  
499 of 63-100% across all ethnicities. Tetramer<sup>+</sup> CD8<sup>+</sup> and CD4<sup>+</sup> T cells were highly activated at  
500 acute timepoints, compared to a less activated profile at follow-up, and mainly expressed  
501 combinations of PD-1 with CD38 and CD71, and HLA-DR to a lesser extent. In contrast to  
502 severe H7N9 influenza<sup>13</sup>, Ebola<sup>46</sup> and COVID-19 disease<sup>39</sup>, with prominent CD38<sup>+</sup>HLA-DR<sup>+</sup>  
503 populations in the total CD8/CD4 compartments, we did not observe marked populations of  
504 CD38<sup>+</sup>HLA-DR<sup>+</sup> T cells in either tetramer<sup>+</sup> or parent populations, perhaps reflecting a less  
505 severe cohort of diseased patients in our DISI study. Nonetheless, we provide acute and  
506 convalescent populations of rare HA<sub>306-318</sub>-specific CD4<sup>+</sup> T cells in H3N2-infected patients that  
507 were HLA-DR\*01:01<sup>+</sup> ( $n=3$ ), HLA-DR\*04:01<sup>+</sup> ( $n=1$ ) or HLA-DR\*11:01<sup>+</sup> ( $n=1$ ), which  
508 complements other studies assessing cells in HLA-DR\*04:01<sup>+</sup> healthy donors and rheumatoid  
509 arthritis patients following influenza vaccination<sup>47,48</sup>. Therefore, our results represent the  
510 broadest array of influenza-specific tetramer<sup>+</sup> T cell responses during acute influenza infection,  
511 providing essential tools for future T cell-immune monitoring of newly-emerging influenza  
512 viruses.

513 Tracking antibody, B and T cell responses (and other immune mediators) may be  
514 predictive of patients' severity or recovery from influenza virus infections that require  
515 hospitalization. Our current analyses of immunological and virological parameters within a  
516 clinical hospital framework provide a unique and key dataset on the mechanisms underpinning  
517 influenza severity and susceptibility in the human population. Furthermore, these efforts  
518 represent a substantial progression to elucidate the host immune responses underlying the  
519 recovery from this acute disease as well as other infectious diseases such as COVID-19<sup>39</sup>.

520

521

## 522 **Online Methods**

### 523 ***Study participants and design***

524 The Dissection of Influenza-Specific Immunity (DISI) cohort enrolled consenting adult patients  
525 admitted to The Alfred hospital during the 2014-2017 peak influenza seasons with influenza-  
526 like illness. Influenza-positive patients were PCR-confirmed ( $n=44$ ), while ILI influenza-  
527 negative patients with other respiratory diseases were treated as negative controls ( $n=20$ ).  
528 Bloods were collected within 24-72 hours of hospital admission (Visit 1, V1), every 2-5 days  
529 until discharge (V2, V3, V4 etc), then followed up approximately 30 days later. Nasal swabs  
530 were collected at V1 and V2 timepoints while in hospital. Clinical data collection included  
531 vaccination status, sequential (sepsis-related) organ failure assessment (SOFA) score<sup>28</sup> as a  
532 measure of disease severity, and any significant risk factors (**Supplementary Tables 1 and 2**).

533 The H7N9-infected hospitalized patient cohort ( $n=18$ ) has previously been described<sup>18</sup>.  
534 Healthy adults vaccinated in 2015 (TIV,  $n=16$ ) and 2016 (QIV,  $n=26$ ) have previously been  
535 described in detail<sup>4</sup>, where blood samples were collected prior to vaccination (day -1 or 0) and  
536 on days 7, 14 and 28 following vaccination. Healthy blood donors were recruited from The  
537 University of Melbourne and Deepdene Surgery. Buffy packs were sourced from Australian Red  
538 Cross Lifeblood, respectively (**Supplementary Table 4**).

539 Human experimental work was conducted according to the Declaration of Helsinki  
540 Principles and according to the Australian National Health and Medical Research Council Code  
541 of Practice. All participants provided written informed consent prior to the study. The study was

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

542 approved by the Alfred Hospital (ID #280/14) and University of Melbourne (ID #1442952.1 and  
543 #1443389.4) Human Research Ethics Committees. Up to 40 mls of DISI patient blood was  
544 collected in sodium heparin tubes (including 1 serum tube) and processed within 24 hours. Up to  
545 60 mls was collected from healthy donors and ~50-60 ml for buffy packs. PBMCs were isolated  
546 by Ficoll-Paque (GE Healthcare, Uppsala, Sweden) density-gradient centrifugation and  
547 cryopreserved. DNA was extracted from the granulocyte layer using a QIAamp DNA Mini Kit  
548 (Qiagen, Hilden, Germany) and sent to the Victorian Transplantation and Immunogenetics  
549 Service (Australian Red Cross Lifeblood, West Melbourne, Victoria, Australia) for HLA class I  
550 and class II molecular typing using the Luminex platform and microsphere technology (One  
551 Lambda, Canoga Park, CA, USA), with LABType SSO HLA typing kits (One Lambda). Nasal  
552 swab samples were kept cold during transport and stored at -80°C within 4 hours.

553 In cases where fewer than the total number of donors were analyzed (**Supplementary**  
554 **Table 6**), DISI patients were selected for influenza-specific cellular assays based on their  
555 influenza status and remaining sample availability, such as the class I and II TAME experiments  
556 which were carried out on IAV<sup>+</sup> patients and relied on HLA type and tetramer availability. HIV-  
557 positive patients ( $n=5$ , **Supplementary Table 2**) were not included in such experiments to fulfil  
558 biocontainment regulations. No other blinding or randomization protocols were applied and no  
559 outliers (i.e. the two death patients) were excluded.

560

### 561 ***IFITM3 SNP analysis***

562 Amplification of *exon 1* rs12252 region was performed by PCR on genomic DNA using forward  
563 (5'-GGAAACTGTTGAGAAACCGAA-3') and reverse (5'-CATACGCACCTTCACGGAGT-  
564 3') primers, as previously described<sup>49</sup>. Amplification of the rs34481144 promotor region was  
565 performed using forward (5'-GGAAACTGTTGAGAAACCGAA-3') and reverse (5'-  
566 CATACGCACCTTCACGGAGT-3') primers, as described<sup>17</sup>.

567

### 568 ***Cytokine analysis***

569 Patient's sera or plasma was diluted 1:4 for performing cytokine bead assay (CBA) using the  
570 Human CBA Kit (BD Biosciences, San Jose, California, USA), according to manufacturer's  
571 instructions. Capture beads included IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-1 $\beta$ ,  
572 IFN- $\alpha$ , MIP-1 $\alpha$ , MIP-1 $\beta$ , MCP-1, CD178/FasL, granzyme B, RANTES, TNF and IFN- $\gamma$ .  
573 Samples were also diluted 1:100 for RANTES. A limited panel of cytokines for H7N9 patients  
574 have already been described<sup>18</sup>.

575

### 576 ***Viral sequencing***

577 Viral isolates from nasal swabs were sequenced for HA using standard Sanger sequencing  
578 methods. HA phylogenetic neighbour-joining trees were produced using Geneious 9.0.4  
579 software. Sequences are on the GISAID database with ID numbers of EPI\_ISL\_312219-312221,  
580 312673-312674.

581

### 582 ***Viruses***

583 Influenza A (A/H1N1/California/7/2009, A/H3N2/Switzerland/9715293/2013 and H3N2/Hong  
584 Kong/4801/2014) and B (B/YAM/Phuket/3073/2013 and B/VIC/Brisbane/60/2008) viruses  
585 were grown in 10-day old embryonated chicken eggs at 33°C for 72 hours. Allantoic fluid was  
586 harvested and titrated using standard plaque assays in MDCK cells for use in the influenza  
587 infection assays. Other viruses (**Supplementary Table 3**) were sourced from the WHO  
588 Collaborating Centre for Reference and Research on Influenza (Melbourne, Australia).

589

### 590 ***Hemagglutination inhibition assay***

591 RDE-treated sera or plasma samples were assessed for antibody titres against a panel of  
592 influenza viruses (**Supplementary Table 3**) using standard HAI assays with 1% turkey red  
593 blood cells (H1N1 and IBV) or 1% guinea pig red blood cells in the presence of oseltamivir  
594 (H3N2), according to WHO guidelines. HAI titres were reported as the reciprocal of the highest

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

595 dilution of serum where hemagglutination was completely inhibited, then divided by 10 and  
596 log<sub>2</sub>-transformed.

597

### 598 *Flow cytometry*

599 Fresh whole blood was used to measure absolute cell numbers using BD TruCount tubes and  
600 BD MultiTest (CD3 FITC/CD16+CD56 PE/CD45 PerCP/CD19 APC, #340500) according to  
601 manufacturer's instructions (BD Biosciences), as well as Tfh and ASC populations as  
602 described<sup>4</sup>. Thawed PBMCs from Flu+ patients were stained with recombinant (r) HA probes  
603 from H1 (California/7/2009), H3 (Switzerland/9715293/2013 or Hong Kong/4801/2014) and B  
604 strains (Phuket/3073/2013 or Brisbane/60/2008)<sup>4,32</sup>, as described, except anti-IgA was not  
605 included in rH1 and rH3 probe panels. PBMCs stained with other antibody panels are indicated  
606 under specific assays. TruCount/MultiTest samples were acquired on a BD CantoII. All other  
607 samples were acquired on a BD LSRII Fortessa. Flow cytometry data were analyzed using  
608 FlowJo v10 software.

609

### 610 *Influenza virus infection assay*

611 Thawed PBMCs (<1.5e6) from DISI Flu+ patients were cultured overnight at 37°C/5% CO<sub>2</sub>  
612 with their cognate live egg-grown virus (MOI=4), essentially as described<sup>4,12</sup>, for a total of 22  
613 hours before cells were harvested, then cell surface and intracellularly stained with Panel 1a or  
614 1b (**Supplementary Table 7**) using the BD Cytotfix/Cytoperm Kit according to manufacturer's  
615 instructions. A no virus culture was included as a background staining control, which was  
616 subtracted from the virus culture.

617

### 618 *Tetramer-associated magnetic enrichment (TAME)*

619 TAME was performed on thawed PBMCs (3-38e6) for the detection of influenza-specific CD4<sup>+</sup>  
620 and CD8<sup>+</sup> T cells, as described<sup>36,37</sup>. Peptide/MHC class I and class II monomers (**Fig. 5a**) were  
621 generated in-house<sup>50,51</sup>, before 8:1 molar ratio conjugation with either PE-streptavidin (SA) or  
622 APC-SA (BD Biosciences) to form tetramers. Briefly, cells were stained (1:100-200 dilution)  
623 with PE- (A2-M1, B7-NP, B8-NPs, B18-NP and B35-NPs) or APC-labelled (A1-NPs, A2-M1,  
624 A24-PB1, A68-NP, B57-NP and DR1/4/11-HAs) tetramers for 1 hour at room temperature  
625 before dual-magnetic enrichment with anti-PE and anti-APC MicroBeads (Miltenyi Biotec,  
626 Bergisch Galdbach Germany) as described<sup>36,38</sup>. Tetramers restricted to the same HLA were  
627 added together at the same dilution. Unenriched, enriched and flow-through fractions were cell  
628 surface stained with Panel 2a (Flu+) or 2b (Flu-, follow-up samples only) (**Supplementary**  
629 **Table 7**), fixed with 1% PFA, then acquired by flow cytometry. Panel 2b samples were fixed  
630 and permeabilized using the eBioscience™ Foxp3/Transcription Factor Staining Buffer Set  
631 (Thermo Fisher Scientific, Carlsbad, CA, USA). Samples with cell events just below 10,  
632 especially for tetramer<sup>+</sup>CD4<sup>+</sup> T cells, were not further characterized phenotypically using these  
633 staining panels.

634

### 635 *Expression of cytolytic molecules*

636 Flow-through fractions of DISI patients following TAME or thawed PBMCs from healthy  
637 donors (**Supplementary Table 4**) were stained with Panel 3 (**Supplementary Table 7**) for  
638 measuring granzymes (A, B, K and M) and perforin using the Foxp3/Transcription Factor  
639 Staining Buffer Set.

640

### 641 *Statistical analyses*

642 Statistical significance was assessed using GraphPad Prism v8 software unless stated otherwise.  
643 Mann-Whitney (unpaired) and Wilcoxin (paired) tests were two-tailed. Friedman (matched) and  
644 Kruskal-Wallis (unmatched) tests were used to compare more than two groups. Tukey's  
645 multiple comparison test compared row means between more than two groups. Partial  
646 correlation plots (**Fig. 1j**) showing significant (FDR-adjusted *p*-value <0.05) coloured squares  
647 were partialled to account for the variance caused by log<sub>10</sub>(age) and the sampling days after  
648 disease onset. To build antibody landscapes (**Fig. 2f**), local regression (LOESS) was applied in  
649 R 3.5.3<sup>52</sup>. LOESS with 95% confidence intervals was also used to plot Fig. 3c, 4c and 4d. Linear

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

650 relationships between day of sample and percent of IFN- $\gamma$  producing cells were assessed with  
651 ordinary least squares (lm function) in R with 95% confidence intervals shaded in grey and  
652 correlation coefficients ( $r^2$ ) reported in Fig 4d. Correlations (**Fig. 3f,g, Supplementary Fig. 4**)  
653 were assessed using Spearman's correlation coefficient ( $r_s$ ). Polyfunctionality pie charts (**Fig.**  
654 **4g**) were generated using Pestle v1.8 and Spice v5 software<sup>53</sup> and  $p$ -values were calculated using  
655 Permutation Test.  $P$ -values lower than 0.05 were considered statistically significant and exact  $p$ -  
656 values are shown in the figure. All statistical tests are indicated in the figure legends.

657

#### 658 **Data availability**

659 The data that support the findings of this study are available from the corresponding author upon  
660 request.

661

662

663

#### 664 **References**

665

- 666 1. G. B. D. Influenza Collaborators. Mortality, morbidity, and hospitalisations due to  
667 influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of  
668 Disease Study 2017. *Lancet Respir Med* **7**, 69-89 (2019).
- 669 2. Iuliano, A.D., *et al.* Estimates of global seasonal influenza-associated respiratory  
670 mortality: a modelling study. *Lancet* **391**, 1285-1300 (2018).
- 671 3. Krammer, F., *et al.* Influenza. *Nat Rev Dis Primers* **4**, 3 (2018).
- 672 4. Koutsakos, M., *et al.* Circulating TFH cells, serological memory, and tissue  
673 compartmentalization shape human influenza-specific B cell immunity. *Sci Transl Med*  
674 **10**(2018).
- 675 5. McMichael, A.J., Gotch, F.M., Noble, G.R. & Beare, P.A. Cytotoxic T-cell immunity to  
676 influenza. *N Engl J Med* **309**, 13-17 (1983).
- 677 6. Epstein, S.L. Prior H1N1 influenza infection and susceptibility of Cleveland Family  
678 Study participants during the H2N2 pandemic of 1957: an experiment of nature. *J Infect*  
679 *Dis* **193**, 49-53 (2006).
- 680 7. Kreijtz, J.H., *et al.* Cross-recognition of avian H5N1 influenza virus by human cytotoxic  
681 T-lymphocyte populations directed to human influenza A virus. *J Virol* **82**, 5161-5166  
682 (2008).
- 683 8. Sridhar, S., *et al.* Cellular immune correlates of protection against symptomatic  
684 pandemic influenza. *Nat Med* **19**, 1305-1312 (2013).
- 685 9. Wilkinson, T.M., *et al.* Preexisting influenza-specific CD4+ T cells correlate with  
686 disease protection against influenza challenge in humans. *Nat Med* **18**, 274-280 (2012).
- 687 10. Zhao, Y., *et al.* High levels of virus-specific CD4+ T cells predict severe pandemic  
688 influenza A virus infection. *Am J Respir Crit Care Med* **186**, 1292-1297 (2012).
- 689 11. Hayward, A.C., *et al.* Natural T Cell-mediated Protection against Seasonal and Pandemic  
690 Influenza. Results of the Flu Watch Cohort Study. *Am J Respir Crit Care Med* **191**,  
691 1422-1431 (2015).
- 692 12. Wang, Z., *et al.* Recovery from severe H7N9 disease is associated with diverse response  
693 mechanisms dominated by CD8(+) T cells. *Nat Commun* **6**, 6833 (2015).
- 694 13. Wang, Z., *et al.* Clonally diverse CD38(+)HLA-DR(+)CD8(+) T cells persist during  
695 fatal H7N9 disease. *Nat Commun* **9**, 824 (2018).
- 696 14. van de Sandt, C.E., *et al.* Human cytotoxic T lymphocytes directed to seasonal influenza  
697 A viruses cross-react with the newly emerging H7N9 virus. *J Virol* **88**, 1684-1693  
698 (2014).
- 699 15. Hertz, T., *et al.* HLA targeting efficiency correlates with human T-cell response  
700 magnitude and with mortality from influenza A infection. *Proc Natl Acad Sci U S A* **110**,  
701 13492-13497 (2013).

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 702 16. Falfan-Valencia, R., *et al.* An Increased Frequency in HLA Class I Alleles and  
703 Haplotypes Suggests Genetic Susceptibility to Influenza A (H1N1) 2009 Pandemic: A  
704 Case-Control Study. *J Immunol Res* **2018**, 3174868 (2018).
- 705 17. Allen, E.K., *et al.* SNP-mediated disruption of CTCF binding at the IFITM3 promoter is  
706 associated with risk of severe influenza in humans. *Nat Med* **23**, 975-983 (2017).
- 707 18. Wang, Z., *et al.* Early hypercytokinemia is associated with interferon-induced  
708 transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. *Proc Natl*  
709 *Acad Sci U S A* **111**, 769-774 (2014).
- 710 19. Lee, N., *et al.* Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal  
711 influenza among hospitalized adults. *PLoS One* **6**, e26050 (2011).
- 712 20. Oshansky, C.M., *et al.* Mucosal immune responses predict clinical outcomes during  
713 influenza infection independently of age and viral load. *Am J Respir Crit Care Med* **189**,  
714 449-462 (2014).
- 715 21. Hall, M.W., *et al.* Innate immune function and mortality in critically ill children with  
716 influenza: a multicenter study. *Crit Care Med* **41**, 224-236 (2013).
- 717 22. Valkenburg, S.A., *et al.* The Hurdles From Bench to Bedside in the Realization and  
718 Implementation of a Universal Influenza Vaccine. *Front Immunol* **9**, 1479 (2018).
- 719 23. Dunning, J., *et al.* Progression of whole-blood transcriptional signatures from interferon-  
720 induced to neutrophil-associated patterns in severe influenza. *Nat Immunol* **19**, 625-635  
721 (2018).
- 722 24. Fox, A., *et al.* Severe pandemic H1N1 2009 infection is associated with transient NK  
723 and T deficiency and aberrant CD8 responses. *PLoS One* **7**, e31535 (2012).
- 724 25. Diao, H., *et al.* Severe H7N9 infection is associated with decreased antigen-presenting  
725 capacity of CD14+ cells. *PLoS One* **9**, e92823 (2014).
- 726 26. Wong, S.S., *et al.* Severe Influenza Is Characterized by Prolonged Immune Activation:  
727 Results From the SHIVERS Cohort Study. *J Infect Dis* **217**, 245-256 (2018).
- 728 27. Quinones-Parra, S., *et al.* Preexisting CD8+ T-cell immunity to the H7N9 influenza A  
729 virus varies across ethnicities. *Proc Natl Acad Sci U S A* **111**, 1049-1054 (2014).
- 730 28. Singer, M., *et al.* The Third International Consensus Definitions for Sepsis and Septic  
731 Shock (Sepsis-3). *JAMA* **315**, 801-810 (2016).
- 732 29. Fonville, J.M., *et al.* Antibody landscapes after influenza virus infection or vaccination.  
733 *Science* **346**, 996-1000 (2014).
- 734 30. Crotty, S. Follicular helper CD4 T cells (TFH). *Annu Rev Immunol* **29**, 621-663 (2011).
- 735 31. Bentebibel, S.E., *et al.* Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with  
736 antibody responses to influenza vaccination. *Sci Transl Med* **5**, 176ra132 (2013).
- 737 32. Liu, Y., *et al.* Cross-lineage protection by human antibodies binding the influenza B  
738 hemagglutinin. *Nat Commun* **10**, 324 (2019).
- 739 33. Wheatley, A.K., Kristensen, A.B., Lay, W.N. & Kent, S.J. HIV-dependent depletion of  
740 influenza-specific memory B cells impacts B cell responsiveness to seasonal influenza  
741 immunisation. *Sci Rep* **6**, 26478 (2016).
- 742 34. Nguyen, T.H., *et al.* Maintenance of the EBV-specific CD8(+) TCRalpha repertoire  
743 in immunosuppressed lung transplant recipients. *Immunol Cell Biol* **95**, 77-86 (2017).
- 744 35. Nguyen, T.H., *et al.* Understanding CD8(+) T-cell responses toward the native and  
745 alternate HLA-A\*02:01-restricted WT1 epitope. *Clin Transl Immunology* **6**, e134  
746 (2017).
- 747 36. Nguyen, T.H.O., *et al.* Perturbed CD8(+) T cell immunity across universal influenza  
748 epitopes in the elderly. *J Leukoc Biol* **103**, 321-339 (2018).
- 749 37. Koutsakos, M., *et al.* Human CD8(+) T cell cross-reactivity across influenza A, B and C  
750 viruses. *Nat Immunol* **20**, 613-625 (2019).
- 751 38. Sant, S., *et al.* Single-Cell Approach to Influenza-Specific CD8(+) T Cell Receptor  
752 Repertoires Across Different Age Groups, Tissues, and Following Influenza Virus  
753 Infection. *Front Immunol* **9**, 1453 (2018).
- 754 39. Thevarajan, I., *et al.* Breadth of concomitant immune responses prior to patient recovery:  
755 a case report of non-severe COVID-19. *Nat Med* **26**, 453-455 (2020).

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

- 756 40. Haltaufderhyde, K., *et al.* Activation of Peripheral T Follicular Helper Cells During  
757 Acute Dengue Virus Infection. *J Infect Dis* **218**, 1675-1685 (2018).
- 758 41. Leong, Y.A., *et al.* CXCR5(+) follicular cytotoxic T cells control viral infection in B cell  
759 follicles. *Nat Immunol* **17**, 1187-1196 (2016).
- 760 42. He, R., *et al.* Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral  
761 infection. *Nature* **537**, 412-428 (2016).
- 762 43. Petrovas, C., *et al.* Follicular CD8 T cells accumulate in HIV infection and can kill  
763 infected cells in vitro via bispecific antibodies. *Sci Transl Med* **9**(2017).
- 764 44. Mylvaganam, G.H., *et al.* Dynamics of SIV-specific CXCR5+ CD8 T cells during  
765 chronic SIV infection. *Proc Natl Acad Sci U S A* **114**, 1976-1981 (2017).
- 766 45. Auladell, M., *et al.* Recalling the Future: Immunological Memory Toward Unpredictable  
767 Influenza Viruses. *Front Immunol* **10**, 1400 (2019).
- 768 46. McElroy, A.K., *et al.* Human Ebola virus infection results in substantial immune  
769 activation. *Proc Natl Acad Sci U S A* **112**, 4719-4724 (2015).
- 770 47. Uchtenhagen, H., *et al.* Efficient ex vivo analysis of CD4+ T-cell responses using  
771 combinatorial HLA class II tetramer staining. *Nat Commun* **7**, 12614 (2016).
- 772 48. Herati, R.S., *et al.* Successive annual influenza vaccination induces a recurrent  
773 oligoclonotypic memory response in circulating T follicular helper cells. *Sci Immunol*  
774 **2**(2017).
- 775 49. Clemens, E.B., *et al.* Towards identification of immune and genetic correlates of severe  
776 influenza disease in Indigenous Australians. *Immunol Cell Biol* **94**, 367-377 (2016).
- 777 50. Gras, S., *et al.* The shaping of T cell receptor recognition by self-tolerance. *Immunity* **30**,  
778 193-203 (2009).
- 779 51. Benati, D., *et al.* Public T cell receptors confer high-avidity CD4 responses to HIV  
780 controllers. *J Clin Invest* **126**, 2093-2108 (2016).
- 781 52. R Core Team. R: A language and environment for statistical computing. R Foundation  
782 for Statistical Computing, Vienna, Austria. (2019. <http://www.R-project.org/>).
- 783 53. Roederer, M., Nozzi, J.L. & Nason, M.C. SPICE: exploration and analysis of post-  
784 cytometric complex multivariate datasets. *Cytometry A* **79**, 167-174 (2011).

785

786

## 787 **Acknowledgements**

788 We thank Jill Garlick, Janine Roney, and the research nurses at the Alfred Hospital, Nicola Bird,  
789 Kim Harland, Louise Carolan and Bernadette McCudden for their technical assistance. Thank  
790 you to Professors David Fairlie and Jim McCluskey for the MR1-5'OP-RU tetramer. We also  
791 thank the study participants for providing blood for research purposes.

792

793

## 794 **Funding**

795 The Australian National Health and Medical Research Council (NHMRC) NHMRC Program  
796 Grant (1071916) to KK, SJT, NLG, AK, DCJ, LEB, WC supported this work. MK and SN were  
797 recipients of Melbourne International Research Scholarship and Melbourne International Fee  
798 Remission Scholarship. CES has received funding from the European Union's Horizon 2020  
799 research and innovation program under the Marie Skłodowska-Curie grant agreement No.  
800 792532. EBC is a NHMRC Peter Doherty Fellow. MA and LH are recipients of Melbourne  
801 International Research Scholarship and Melbourne International Fee Remission Scholarship. SS  
802 was a recipient Victoria India Doctoral Scholarship and Melbourne International Fee Remission  
803 Scholarship, University of Melbourne. The Melbourne WHO Collaborating Centre for  
804 Reference Research on Influenza is supported by the Australian Government Department of  
805 Health. SG is a NHMRC SRF-Level A Fellow. JR is supported by an ARC Laureate fellowship.  
806 NLG is supported by a NHMRC Ideas grant, ARC Discovery Project and ARC Future  
807 Fellowship. PGT is supported by the St. Jude Center of Excellence for Influenza Research and  
808 Surveillance (NIAID Contract HHSN27220140006C), R01 AI 107625, R01AI136514 and  
809 ALSAC. ACC is a NHMRC Career Development (level 2) Fellow. KK was supported by a

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

810 NHMRC Senior Research Fellowship Level B (#1102792), NHMRC Investigator Grant  
811 (#1173871) and the University of Melbourne Dame Kate Campbell Fellowship.

812

813

#### 814 **Conflicts of interest**

815 The authors declare no conflict of interest.

816

#### 817 **Author contributions**

818 KK supervised and lead the study. KK, THON, MK, CES and LL designed the experiments.  
819 THON, MK, CES, LL, LG, SS, EBC, MAu, LH, ZW, SN, AF, XX, MAb, KLL and YD  
820 performed experiments. THON, MK, CES, JCC, LL, LG, EKA, TB, EBC, MAu, LH, ACH,  
821 PGT and KK analyzed data. AKW and SJK provided invaluable rHA probes. SG and JR  
822 provided invaluable pMHC-I/II tetramers. JC, JX, TCK and ACC recruited the patient cohorts.  
823 KK, ACC, TCK, SJK, PCD, DJ, LEB, NLG and WC provided intellectual input into the study  
824 design and data interpretation. THON, PGT, ACC and KK wrote the manuscript. All authors  
825 reviewed and approved the manuscript.

826

#### 827 **Competing interests**

828 All authors declare no competing interests.

829

#### 830 **Figure legends**

831 **Fig. 1. Clustering analysis of patient clinical information, genetic characteristics and**  
832 **inflammatory cytokines. a,** Flow chart of study design. **b,** Frequency of patients infected with  
833 seasonal influenza virus strains. *N* values are below for total and for each year. **c,** Age  
834 distribution by influenza A (3 unsubtype, 7 H1N1, 24 H3N2), influenza B (3 unsubtype, 4  
835 YAM, 3 VIC) and influenza-negative (Non-flu, Flu-) patients (*n*=20). Virus strain colours match  
836 those in **(b)**. **d,** Days in hospital for DISI cohort and H7N9 cohort. **c,d,** Bars indicate the median  
837 and IQR, statistical significance (*p*<0.05) was determined using the Kruskal-Wallis test. **e,**  
838 Frequency of universal versus risk HLA alleles between influenza-positive (Flu+) and Flu-  
839 patients. **f,g,** Pie charts of IFITM3 SNP allele genotyping at positions rs12252 and rs34481144,  
840 respectively (risk allele in black). **h,** Box plots of rs34481144 alleles against SOFA scores  
841 showing median, IQR and whiskers extending to the largest or smallest values no further than  
842 1.5 times the IQR. **i,** Representative serum levels and distribution of pro-inflammatory cytokines  
843 in patients, measured within the first 2-3 days of hospital admission (Visit 1, V1), with varying  
844 disease severity. **j,** Partial correlation plots showing the degree of correlation between every  
845 chemokine/cytokine pair in Flu+ patients at V1 and *F*<sub>up</sub>. The colour corresponds to the  
846 correlation coefficient and the size of the colored squares correspond to the FDR-adjusted *p*-  
847 value. Correlations that are not significant (*p*>0.05) result in white boxes.

848

849 **Fig. 2. Viral analysis and antibody responses. a,** H3N2 phylogenetic tree of HA amino acid  
850 sequences from previous WHO reference strains in black, influenza vaccine strains in red and  
851 sequences isolated from the nasal swab of 12 H3N2-infected patients in blue. Patient number is  
852 followed by the year of recruitment, yes (Y) or no (N) for prior vaccination in the year of  
853 infection, and “mm\*” indicates whether the vaccine was a clade mismatch in that year. Scale bar  
854 represents the number of substitutions per site. **b,** Antibody HAI titers of Flu+ patients at acute  
855 (V1 or V2) and follow-up timepoints from the relevant infected strain (mean and SD are  
856 shown). Statistical significance (*p*<0.05) was determined using the Mann-Whitney test between  
857 acute and follow-up per strain. **c,d,** Geometric mean titers (GMT) per strain in Flu+ and Flu-  
858 patients at acute and follow-up, and from a healthy vaccinated cohort at days 0 and 28 post-  
859 vaccination. **b-d,** Both H1N1 and H3N2 titers are shown for three A/unsubtyped patients and  
860 both B/YAM/Phuket/3073/2013 and B/VIC/Brisbane/60/2008 titres are shown for three  
861 B/unsubtyped patients (square symbols). **e,** Representative antibody landscapes from a patient  
862 infected with H1N1, H3N2, B/YAM or B/VIC virus. Blue shading indicate period of potential  
863 exposure based on the year born. **f,** Antibody landscapes of H1N1- and H3N2-infected (*n*=7 and  
864 23, respectively) and H1N1- and H3N2-non-infected patients (*n*=45 and 29, respectively). Lines



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

865 and shading indicate the GMT and 95% confidence intervals, respectively. Gradient coloured  
866 dots indicate individual titres.

867

868 **Fig. 3. Circulating Tfh cells, ASCs and influenza-specific B cell responses.** **a**, Representative  
869 FACS plots of CD4<sup>+</sup>CXCR5<sup>+</sup> cTfh subsets (cTfh1/2/17) and expression of activation markers  
870 PD-1 and ICOS. **b**, Representative FACS plots of CD19<sup>+</sup>CD20<sup>-lo</sup>CD27<sup>++</sup>CD38<sup>++</sup> ASCs and PD-  
871 1<sup>+</sup>ICOS<sup>+</sup> activated CXCR3<sup>+</sup>CCR6<sup>-</sup> cTfh1 cells at acute (V1 and V2) and follow-up (F<sub>up</sub>)  
872 timepoints. Days (d) after disease onset are shown in brackets. **c**, Numbers of ASC and cTfh1  
873 cells of Flu+ (red) and Flu- (blue) patients after disease onset. Grey shading represents 95%  
874 confidence intervals. **d**, Numbers of the peak ASC responses during acute ILI (Ac<sub>max</sub>) versus F<sub>up</sub>  
875 in Flu+ (open circles, Ac<sub>max</sub> n=40, F<sub>up</sub> n=32) and Flu- patients (grey circles, Ac<sub>max</sub> n=19, F<sub>up</sub>  
876 n=15). **e**, Peak cTfh responses of different Tfh1/2/17 subsets at Ac<sub>max</sub> (Flu+ n=40, Flu- n=19)  
877 and F<sub>up</sub> (Flu+ n=32, Flu- n=15) timepoints. **f**, Correlation (Spearman correlation coefficient, r<sub>s</sub>)  
878 between Ac<sub>max</sub> ASC and cTfh1 responses and **(g)** Ac<sub>max</sub> ASC responses with HAI antibody titres  
879 of high (HAI≥40) and low responders (HAI<40) during acute infection. **h**, Representative FACS  
880 plots of H1-, H3- and B-specific rHA<sup>+</sup> B cells at V1 and F<sub>up</sub> timepoints (days after disease onset  
881 in brackets). **i**, Numbers of total rHA<sup>+</sup> B cells and per H1-, H3- and B-specific rHA<sup>+</sup> B cells at  
882 acute (Ac) (n=21) and F<sub>up</sub> timepoints (n=22). **j**, Representative overlay FACS plots of live total  
883 B cells and rHA<sup>+</sup> B cells from IBV-infected patient #29 at F<sub>up</sub> for phenotype and isotype  
884 characterization. **k-m**, Phenotype (top panel) and isotype (bottom panel) distributions of **(k)**  
885 total B cells and **(l)** rHA<sup>+</sup> B cells in Flu+ patients at acute (Ac=V1 and V2, V1, V2) and follow-  
886 up timepoints in comparison to **(m)** healthy vaccinated controls (n=41) pre-vaccination at  
887 baseline (BL) and d7, 14 and 28 post-vaccination. **d,e,i**, Red bars indicate the median and IQR  
888 for cell numbers. **k-m**, Bars indicate the mean and SD for frequencies. Statistical significance  
889 (p<0.05) was determined using the **(d)** Mann-Whitney test, **(e)** Friedman test and **(k-m)** Tukey's  
890 multiple comparison test. Coloured p-values refer to each group legend within the graph.

891

892 **Fig. 4. Innate and adaptive immune responses in seasonal influenza-infected patients.** **a-d**,  
893 Data following influenza virus infection assay. **a**, Representative FACS plots of innate (NK  
894 cells, γδ T cells and CD161<sup>+</sup>TRAV1-2<sup>+</sup> MAIT cells) and adaptive (CD4<sup>+</sup> and CD8<sup>+</sup> T cells)  
895 immune cell subsets gated on live/CD14<sup>-</sup>/CD19<sup>-</sup> singlet lymphocytes. **b**, Representative FACS  
896 plots measuring frequency of infection (intracellular nucleoprotein (NP) staining) and IFN-γ  
897 production for each immune cell subset. Infection in PBMCs by intracellular NP-staining  
898 showing consistent infectivity rates over time across the donors (**Supplementary Fig. 5b**).  
899 MAIT cells were defined as CD161<sup>+</sup>TRAV1-2<sup>+</sup> and were validated by the MR1-5<sup>+</sup>OP-RU-  
900 tetramer in 51% of samples (**Supplementary Fig. 5c,d**). **c,d**, Numbers (n=22) and frequencies  
901 (n=30) of influenza-specific IFN-γ-production in patients' immune cell subsets as days of  
902 disease onset where 95% confidence intervals are shaded in grey. **e-g**, Patient data from PBMCs  
903 left over from flow through fraction following TAME. \*NK cells were defined by live/CD14<sup>-</sup>  
904 /CD19<sup>-</sup>/CD3<sup>-</sup> cells. ^MAIT cells were defined by the MR1-5-OP-RU-tetramer and anti-TRAV1-  
905 2 antibody. **e**, Frequency (mean, SD) of Flu+ patient cells expressing total cytotoxic molecules  
906 at acute (includes n=16 at V1 and n=11 at subsequent visits i.e. V2, V3, or V4) and follow-up  
907 timepoints (n=19), in comparison to healthy donors (n=20, except for MAIT subset where  
908 n=12). **f**, Representative FACS plots of CD8<sup>+</sup> T cells from Flu+ patient and individual  
909 frequencies (mean, SD) of granzymes (A, B, K and M) and perforin staining for each cell  
910 subset. **g**, Pie charts representing the average fractions of cells co-expressing different cytotoxic  
911 molecules (slices) and the combinations of granzymes and perforin molecules (arcs). Statistical  
912 significance (p<0.05) was determined using **(e,f)** Tukey's multiple comparison and **(g)**  
913 Permutation tests.

914

915 **Fig. 5. Influenza-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses.** **a**, List of influenza-specific HLA  
916 class I (A, B) and class II (DR) tetramers used in the study. **b,c**, Concatenated FACS plots of  
917 TAME-enriched class I-tetramer<sup>+</sup> cells gated on CD8<sup>+</sup> T cells from Flu+ patients and **(d)** Flu-  
918 patients. Individual tetramer precursor frequencies are shown below for patients in **(b)**. **e**,

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

919 Concatenated FACS plots of TAME-enriched class II-tetramer<sup>+</sup> cells gated on CD4<sup>+</sup> T cells  
920 from H3N2-infected patients. **f**, Precursor frequencies of tetramer<sup>+</sup> cells from Flu+ and Flu-  
921 patients at acute (V1, V2, V3 or V4) and follow-up timepoints. **g**, Representative overlay FACS  
922 plots of activation markers expressed on TAME-enriched tetramer<sup>+</sup> cells compared to their  
923 unenriched parent population. **h**, Frequency of A2-M1<sup>+</sup>CD8<sup>+</sup> T cells from individual Flu+ and  
924 Flu- patients expressing different combinations of activation markers PD-1, CD38, HLA-DR  
925 and CD71, where CD71 was replaced by Ki-67 in the staining panel for Flu- patients. **i**, Overall  
926 activation status of TAME-enriched tetramer<sup>+</sup> cells compared to their unenriched parent  
927 population of CD4<sup>+</sup> or CD8<sup>+</sup> T cells in Flu+ patients. **j**, T cell differentiation phenotype of  
928 TAME-enriched tetramer<sup>+</sup> cells in relation to the unenriched parent population of CD4<sup>+</sup> or CD8<sup>+</sup>  
929 T cells. **i,j**, Mean and SD are shown for all acute and follow-up timepoints, except for the acute  
930 tetramer<sup>+</sup>CD4<sup>+</sup> group ( $n=2$ ), which were plotted individually. Statistical significance ( $p<0.05$ )  
931 was determined using Tukey's multiple comparison test for **(i)** number of activation markers  
932 present (0, 1 or 2+) and **(j)** T cell differentiation subsets.

933  
934 **Fig. 6. Analyses of immune responses and clinical and genetic host factors. a,b,**  
935 Unsupervised heatmaps of immune, clinical and genetic parameters in Flu+ patients at **a**, acute  
936 and **b**, convalescent timepoints. Interactive heatmaps (.html) are shown in **Supplementary Fig.**  
937 **8a-e** for Flu+, Flu- and combined datasets. Regions of low (maroon) and high (pink) cytokine  
938 clusters are boxed. **c**, Box plots of IFN- $\gamma$ -producing cells following influenza virus infection  
939 assay, at the earliest acute (V1) and convalescent (F<sub>up</sub>) timepoints as a function of patients'  
940 disease severity via binned SOFA scores of 0-1 versus 2-6. Median, IQR and whiskers  
941 extending to the largest or smallest values no further than 1.5 times the IQR are shown.  
942 Nonparametric Wilcoxon rank sum test with continuity correction was used for comparisons  
943 between SOFA categories. Wilcoxon signed rank test (a paired test) was used to compare  
944 differences between V1 and F<sub>up</sub> among the same individuals. Tests were carried out on the  
945 actual data, although plots were on a log<sub>10</sub>+1 scale for ease of visualization.




Figure 1 Nguyen et al.






Figure 2 Nguyen *et al.*




Figure 3 Nguyen *et al.*




Figure 4 Nguyen *et al.*




Figure 5 Nguyen *et al.*




Figure 6 Nguyen *et al.*